Nikolaos Kanellias - Publications

The prognostic value of red blood cell distribution width in AL amyloidosis.

Journal: Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis

Published: May 16, 2026

Management and long-term haematological and neurological outcomes of Immunoglobulin M and Waldenström's macroglobulinaemia-related neuropathy: A single-centre experience.

Journal: British journal of haematology

Published: April 27, 2026

A Prospective Study of Familial Predisposition in Plasma Cell Dyscrasias.

Journal: Blood advances

Published: March 11, 2026

Validation of the new IMS/IMWG consensus genomic staging (CGS) of high-risk multiple myeloma (HRMM) in a contemporary cohort of 1209 patients.

Journal: HemaSphere

Published: March 09, 2026

Can Exercise Training Improve the Quality of Life and Physical Function in Multiple Myeloma Patients?: Discussing the Progression of the Training Stimulus.

Journal: Sports (Basel, Switzerland)

Published: December 18, 2025

Characteristics and clinical course of younger patients with asymptomatic monoclonal gammopathies.

Journal: British journal of haematology

Published: November 25, 2025

Clinical outcomes in newly diagnosed patients with Waldenström's macroglobulinaemia treated in a tertiary academic centre.

Journal: British journal of haematology

Published: September 15, 2025

Belantamab mafodotin, lenalidomide and dexamethasone (BelaRd) in newly diagnosed intermediate-fit and frail myeloma.

Journal: Blood

Published: September 11, 2025

Belantamab mafodotin, lenalidomide, and dexamethasone for intermediate-fit and frail patients with newly diagnosed myeloma.

Journal: Blood

Published: September 11, 2025

Bone disease burden does not impact overall survival in newly diagnosed patients with multiple myeloma - a single center, retrospective imaging analysis on 119 patients.

Journal: Journal of bone oncology

Published: August 04, 2025

Enhanced Risk Stratification of Smoldering Multiple Myeloma with Dynamic Biomarkers: A Multinational, Multicenter Study including 2,270 Participants (PANGEA 2.0).

Journal: Research square

Published: June 12, 2025

Enhanced dynamic risk stratification of smoldering multiple myeloma.

Journal: Nature medicine

Published: May 19, 2025